In an attempt to further improve the DFS of this special subtype of breast cancer patients, investigators studied an extended adjuvant treatment with neratinib, a pan-HER2 inhibitor, for one year after completing a full year of trastuzumab in the ExteNET trial. This evidence concerns the gene ERBB2 and breast carcinoma.